Overview of UK indications
Medicines in the UK are granted marketing authorisations (licenses) by the Medicines and Healthcare products Regulatory Agency (MHRA) based on clinical trial evidence. Pregabalin is unique because its mechanism—calming hyper-excitable neurons—allows it to treat conditions spanning neurology, psychiatry, and pain medicine.
| Indication | UK Status | Typical Patient Context |
|---|---|---|
| Peripheral Neuropathic Pain | Licensed (NHS recommended) | Diabetic neuropathy, post-herpetic neuralgia (after shingles), nerve root trauma |
| Central Neuropathic Pain | Licensed (NHS recommended) | Spinal cord injury pain, post-stroke central pain, multiple sclerosis neuropathic pain |
| Generalised Anxiety Disorder | Licensed (NICE stepped care) | Chronic anxiety and excessive worry, often when SSRIs/SNRIs are ineffective or not tolerated |
| Focal (Partial) Epilepsy | Licensed (Adjunctive therapy) | Used alongside other anti-seizure medicines when monotherapy is insufficient |
| Fibromyalgia | Off-label in UK | Specialist pain clinic care for central sensitization pain |
| Sciatica (Radicular Pain) | Off-label (Not routinely recommended) | Occasionally trialled, though clinical trials show limited benefit over placebo |
1. Neuropathic (nerve) pain
Neuropathic pain arises directly from damage or disease affecting the somatosensory nervous system. Patients frequently describe neuropathic pain as burning, stabbing, shooting, electric shocks, freezing, or tingling ("pins and needles"). Ordinary non-opioid analgesics like paracetamol and ibuprofen are ineffective because they target peripheral tissue inflammation rather than malfunctioning nerve transmission.
Under NICE Guideline CG173, Pregabalin is recommended as a first-line pharmacological option (alongside amitriptyline, duloxetine, and gabapentin) for:
- Diabetic peripheral neuropathy: Nerve damage in the feet and lower legs caused by prolonged elevated blood glucose.
- Post-herpetic neuralgia: Persistent nerve pain lasting months or years after a herpes zoster (shingles) rash has resolved.
- Trigeminal neuralgia: Severe facial shooting pain, usually as secondary therapy or adjunct.
- Central neuropathic pain: Constant burning or aching resulting from stroke or spinal cord injury.
For more detailed clinical evidence, see our comprehensive guide to Pregabalin for nerve pain.
2. Generalised anxiety disorder (GAD)
Generalised anxiety disorder is characterised by excessive, uncontrollable worry about everyday situations, accompanied by physical symptoms such as muscle tension, motor restlessness, sleep disruption, and autonomic arousal (racing heart, sweating, digestive distress).
Unlike selective serotonin reuptake inhibitors (SSRIs) such as sertraline or escitalopram, which typically require 3 to 6 weeks to take effect, Pregabalin often begins reducing physical anxiety symptoms within the first week of treatment.
Under NICE Guideline CG113, Pregabalin is generally positioned for patients who cannot tolerate or have not benefited from SSRIs or SNRIs. Because of the risk of physical dependence and tolerance, prescribers must carefully evaluate history of substance misuse before initiating therapy. Read our dedicated guide on Pregabalin for anxiety.
3. Focal epilepsy (add-on treatment)
In epilepsy management, Pregabalin is approved as an adjunctive (add-on) treatment for adults experiencing focal seizures (previously termed partial seizures), with or without secondary generalisation into bilateral tonic-clonic convulsions.
It is not used as a solo first-line treatment (monotherapy). Instead, neurologists add Pregabalin to an existing anti-epileptic drug regimen (such as lamotrigine, levetiracetam, or carbamazepine) when seizures remain poorly controlled. Strict adherence to dosing schedules is vital, as missed doses can trigger breakthrough seizures. Learn more in our Pregabalin for epilepsy guide.
Off-label prescribing in the UK
In UK medicine, "off-label" prescribing refers to using a licensed drug for an unapproved condition, at an unapproved dose, or in an unapproved patient population. Doctors may legally prescribe off-label under General Medical Council (GMC) guidelines if they believe, based on sound clinical rationale or medical literature, that it serves the patient’s best interest.
- Fibromyalgia: While Pregabalin is FDA-approved for fibromyalgia in the United States, it is not licensed for this indication in the UK. NICE guidelines for chronic primary pain (NG193) recommend against starting gabapentinoids for chronic widespread pain, but some specialist tertiary pain centres trial it where other options have failed. Read our Pregabalin for fibromyalgia guide.
- Sciatica: Although commonly trialled for leg nerve pain stemming from herniated lumbar discs, major trials (including the landmark PRECISE trial) found Pregabalin no more effective than placebo for acute sciatica, while causing higher side effect rates. Read our Pregabalin for sciatica guide.
- Restless Legs Syndrome (RLS): Neurologists occasionally prescribe low-dose Pregabalin off-label for severe, refractory restless legs symptoms.
What Pregabalin does NOT treat
Pregabalin is ineffective and inappropriate for:
- Mechanical lower back pain, lumbago, or muscle strains
- Osteoarthritis or rheumatoid arthritis joint inflammation
- Tension-type headaches and episodic migraine (unless specialist-prescribed)
- Acute post-operative surgical pain without a clear neuropathic component
- Depressive episodes (it is not an antidepressant)
Effectiveness: What should patients realistically expect?
In chronic pain trials, clinical efficacy is assessed by the proportion of patients achieving at least a 30% to 50% reduction in pain score. On average, across neuropathic pain conditions:
- Approximately 35% to 50% of patients experience meaningful, clinically noticeable pain reduction.
- A significant proportion of patients do not experience adequate relief or discontinue therapy early due to intolerable side effects (such as dizziness, sedation, or brain fog).
Because individual response varies dramatically, NICE guidelines recommend formal clinical review after 4 to 8 weeks to determine whether treatment provides sufficient benefit to justify continuing.
Questions to discuss with your prescriber
- Is my pain proven to be neuropathic rather than musculoskeletal or inflammatory?
- What is the realistic treatment goal (e.g., improved sleep, 30% pain reduction, better mobility)?
- How long will we trial the medication before deciding whether to continue?
- What is the plan if I experience persistent dizziness or concentration problems?
Clinical sources and references
- NICE CG173: Neuropathic pain in adults: pharmacological management
- NICE CG113: Generalised anxiety disorder and panic disorder in adults
- NICE NG217: Epilepsies in children, young people and adults
- BNF: Pregabalin indications and dose guidance
- GMC: Good practice in prescribing and managing medicines and devices